EA201590247A1 - Антитела к siglec-15 - Google Patents

Антитела к siglec-15

Info

Publication number
EA201590247A1
EA201590247A1 EA201590247A EA201590247A EA201590247A1 EA 201590247 A1 EA201590247 A1 EA 201590247A1 EA 201590247 A EA201590247 A EA 201590247A EA 201590247 A EA201590247 A EA 201590247A EA 201590247 A1 EA201590247 A1 EA 201590247A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
siglec
bone
antigen
binding fragments
Prior art date
Application number
EA201590247A
Other languages
English (en)
Inventor
Мэттью Стюибль
Жилль Бернар Тремблэ
Трейен Сулеа
Анна Н. Морайтис
Марио Филион
Original Assignee
Алетиа Байотерапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алетиа Байотерапьютикс Инк. filed Critical Алетиа Байотерапьютикс Инк.
Publication of EA201590247A1 publication Critical patent/EA201590247A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В данном документе описаны антитела и антигенсвязывающие фрагменты, которые специфически связываются с Siglec-15. Такие антитела или антигенсвязывающие фрагменты могут обладать способностью подавлять дифференцировку остеокластов и/или способностью подавлять активность остеокластов в отношении резорбции кости. Также в данном документе раскрыты композиции и клетки, экспрессирующие антитела к Siglec-15 или антигенсвязывающие фрагменты. Антитела к Siglec-15 также могут быть пригодны для лечения потери костной массы или заболеваний костей. Также описаны способы выявления или диагностики потери костной массы или заболеваний, связанных с костями.
EA201590247A 2012-07-19 2013-07-17 Антитела к siglec-15 EA201590247A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261673442P 2012-07-19 2012-07-19
US201361777049P 2013-03-12 2013-03-12
US201361810415P 2013-04-10 2013-04-10
PCT/CA2013/000646 WO2014012165A1 (en) 2012-07-19 2013-07-17 Anti-siglec-15 antibodies

Publications (1)

Publication Number Publication Date
EA201590247A1 true EA201590247A1 (ru) 2015-10-30

Family

ID=49948128

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590247A EA201590247A1 (ru) 2012-07-19 2013-07-17 Антитела к siglec-15

Country Status (15)

Country Link
US (1) US9493562B2 (ru)
EP (1) EP2875051B1 (ru)
JP (1) JP6268173B2 (ru)
KR (1) KR20150036274A (ru)
CN (1) CN104507969A (ru)
AU (1) AU2013293062A1 (ru)
CA (2) CA2876517C (ru)
EA (1) EA201590247A1 (ru)
ES (1) ES2723885T3 (ru)
HK (1) HK1210192A1 (ru)
IL (1) IL236259A0 (ru)
IN (1) IN2014KN02933A (ru)
MX (1) MX2015000863A (ru)
WO (1) WO2014012165A1 (ru)
ZA (1) ZA201409358B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
JP6268173B2 (ja) 2012-07-19 2018-01-24 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
EP3157562A4 (en) * 2014-06-18 2017-12-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
KR20180098570A (ko) * 2016-01-12 2018-09-04 고쿠리츠 다이가쿠 호우징 지바 다이가쿠 항-ｍｙｌ9 항체
KR102370762B1 (ko) * 2016-03-31 2022-03-04 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 이의 사용 방법
BR112019005292A2 (pt) 2016-09-21 2019-09-03 Nextcure Inc anticorpos para siglec-15 e métodos de uso dos mesmos.
MA46770A (fr) * 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2019114793A1 (zh) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US20230174627A1 (en) * 2019-05-14 2023-06-08 Jeffrey W. FROUDE Antibodies to sudan and ebola virus
WO2021178749A2 (en) * 2020-03-05 2021-09-10 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
JP7364315B2 (ja) * 2020-03-27 2023-10-18 ビオシオン インコーポレイテッド 抗体結合Ｓｉｇｌｅｃ１５及びその使用
EP4242231A1 (en) * 2020-11-05 2023-09-13 Shanghai JMT-Bio Technology Co., Ltd. Anti-siglec-15 antibody and application thereof in preparing drug
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN112961214B (zh) * 2021-03-19 2022-08-02 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN114591434B (zh) * 2021-04-30 2023-02-28 杭州邦顺制药有限公司 抗Siglec15抗体及其制备方法和用途
WO2022237819A1 (zh) * 2021-05-13 2022-11-17 信达生物制药(苏州)有限公司 抗Siglec-15抗体及其用途
CN114395042B (zh) * 2022-03-28 2022-06-10 北京科诺信诚科技有限公司 抗il-33人源化抗体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4554162A (en) 1984-05-04 1985-11-19 Warner-Lambert Company CL-1724 Antibiotic compounds, their production and use
US4539203A (en) 1984-11-13 1985-09-03 Warner-Lambert Company CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4837206A (en) 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
LU87693A1 (fr) 1990-03-07 1991-10-08 Wurth Paul Sa Sonde de prise d'echantillons gazeux et de mesures thermiques dans un four a cuve
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5817303A (en) 1995-05-05 1998-10-06 Protein Polymer Technologies, Inc. Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer
US5712127A (en) 1996-04-29 1998-01-27 Genescape Inc. Subtractive amplification
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
AU2980199A (en) 1998-03-04 1999-09-20 Genencor International, Inc. Modified forms of pullulanase
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US7060433B1 (en) 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
DK1967586T3 (da) 2000-01-26 2011-06-20 Agensys Inc 84P2A9: prostata- og testikelspecifikt protein med høj ekspression ved prostatacancer
US7585839B2 (en) 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
WO2002016590A2 (en) 2000-08-21 2002-02-28 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
WO2002020822A2 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
AU2002233994A1 (en) 2000-11-08 2002-05-21 Incyte Genomics, Inc. Secreted proteins
CN100336521C (zh) 2000-12-12 2007-09-12 血管实验室公司 蜜蜂花叶提取物制备抑制血管生成相关疾病药物的用途
US7459539B2 (en) 2000-12-15 2008-12-02 Agensys, Inc. Antibody that binds zinc transporter protein 108P5H8
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040076992A1 (en) 2001-02-15 2004-04-22 Yusuke Nakamura Novel cell adhesion molecule specific to activated leukocyte
KR100891157B1 (ko) 2001-03-28 2009-04-07 헬릭스 바이오메딕스, 인코포레이티드 짧은 생물활성 펩티드 및 그것들의 사용 방법
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6967021B2 (en) 2001-04-27 2005-11-22 Trustees Of Tufts College Use of Galectin-3 to promote the re-epithelialization of wounds
DE60225545T2 (de) 2001-05-07 2009-04-02 National Research Council Of Canada, Ottawa Verstärkte herstellung rekombinanter proteine mittels transienter transfektion von in suspension wachsenden säugerzellen
JP2004529740A (ja) 2001-06-15 2004-09-30 ジョーンズ ホプキンズ シンガポール ピーティーイー リミテッド 生体機能繊維
SG173211A1 (en) 2001-06-26 2011-08-29 Amgen Inc Antibodies to opgl
CA2652991A1 (en) 2001-07-16 2003-11-13 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US7033991B2 (en) 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
US20090075377A1 (en) 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US7402664B2 (en) 2002-09-03 2008-07-22 Genencor International, Inc. Nucleic acids and expression vectors comprising carotenoid binding peptides
JP4120778B2 (ja) 2001-09-26 2008-07-16 国立大学法人 奈良先端科学技術大学院大学 骨代謝異常疾患マーカー及びその利用
AU2002364699A1 (en) 2001-11-13 2003-06-17 Incyte Genomics, Inc. Receptors and membrane-associated proteins
JP2003210166A (ja) 2001-11-16 2003-07-29 Sanyo Chem Ind Ltd 変温動物由来細胞の細胞接着基材
US20080318871A1 (en) 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080194489A1 (en) 2001-12-21 2008-08-14 Khan Nisar A Treatment of iatrogenic disease
US20080242837A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20080242618A1 (en) 2001-12-21 2008-10-02 Khan Nisar A Stratification
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
EP1487870A2 (en) 2002-01-09 2004-12-22 Université de Lausanne Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7514407B2 (en) 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
US8298606B2 (en) 2002-03-08 2012-10-30 The Regents Of The University Of California Methods and compositions for stabilizing the myocardium
AU2003210054A1 (en) 2002-03-21 2003-10-08 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20040102608A1 (en) 2002-05-13 2004-05-27 Cornell Research Foundation, Inc. Multiblock copolymers having improved mechanical properties
WO2003096990A2 (en) 2002-05-17 2003-11-27 Montana State University Protein cages for the delivery of medical imaging and therapy
BRPI0311822B8 (pt) 2002-06-06 2021-05-25 Oncotherapy Science Inc composição farmacêutica para o tratamento de câncer
US7357929B2 (en) 2002-06-28 2008-04-15 D. Collen Research Foundation Vzw Placental growth factor as a target for the treatment of osteoporosis
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
EP2431048B1 (en) 2002-10-08 2015-03-11 Danisco US Inc. Phenolic binding peptides
EP1565203B1 (en) 2002-11-01 2013-11-20 Trustees Of Tufts College Templated native silk smectic gels
EP2317317B1 (en) 2002-12-03 2014-11-26 North Carolina State University Prion protein ligands and methods of use
JP2004189848A (ja) 2002-12-10 2004-07-08 Giken:Kk 炭化処理方法および炭化処理システム
DK2259068T3 (en) 2003-01-16 2013-11-11 Caprotec Bioanalytics Gmbh Capture compounds and methods for analyzing the proteome
JP3906924B2 (ja) 2003-02-28 2007-04-18 独立行政法人農業生物資源研究所 絹タンパクから細胞生育ペプチドの抽出と利用
WO2004085650A1 (en) 2003-03-24 2004-10-07 The University Of Hong Kong A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars)
WO2004085633A1 (en) 2003-03-24 2004-10-07 The University Of Hong Kong A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2005012606A2 (en) 2003-04-10 2005-02-10 Tufts University Concentrated aqueous silk fibroin solution and use thereof
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
JP3915983B2 (ja) 2003-05-27 2007-05-16 ゼライス株式会社 プロテアーゼ、このプロテアーゼをコードするｄｎａ、プロテアーゼの製造方法
CA2529125A1 (en) 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
FR2860237B1 (fr) 2003-09-30 2006-03-10 Centre Nat Rech Scient Polypeptide d'interaction comprenant un motif heptapeptidique et un domaine de penetration cellulaire
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
US20090226374A1 (en) 2003-10-27 2009-09-10 Health Aide, Inc. Anaphylatoxins for detecting clinical conditions
US20050153333A1 (en) 2003-12-02 2005-07-14 Sooknanan Roy R. Selective terminal tagging of nucleic acids
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
US20090227505A1 (en) 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
WO2005066337A2 (en) 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
US8338138B2 (en) 2004-01-28 2012-12-25 The John Hopkins University Methods for making and using molecular switches involving circular permutation
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
CN101124261A (zh) 2004-03-01 2008-02-13 派普特拉医药有限公司 酪蛋白衍生肽及其治疗用途
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2005098043A2 (en) 2004-03-30 2005-10-20 The President And Fellows Of Harvard College Ligand-dependent protein splicing
US7253273B2 (en) 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
US7189697B2 (en) 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
US7603239B2 (en) 2004-05-05 2009-10-13 Massachusetts Institute Of Technology Methods and systems for generating peptides
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
JP2008509157A (ja) 2004-08-06 2008-03-27 ソフェリオン セラピューティクス，インコーポレイテッド 抗血管新生ペプチドおよびその使用方法
JP2006068378A (ja) 2004-09-03 2006-03-16 Terumo Corp 血管内留置物
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
CA2583399A1 (en) 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
WO2006050611A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
US8022040B2 (en) 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
JP2008522632A (ja) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列
EP1846015A4 (en) 2005-01-19 2009-08-12 Mathew Mark Zuckerman METHOD, COMPOSITIONS AND CLASSIFICATION FOR TUMOR DIAGNOSIS AND TREATMENT
DK1844074T3 (da) 2005-02-03 2013-07-15 Antitope Ltd Humane antistoffer og proteiner
DK1853620T3 (da) 2005-02-09 2012-03-26 Helix Biomedix Inc Antimikrobielle hexapeptider
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
JP2008539209A (ja) 2005-04-26 2008-11-13 カリヨン−シーティーティー リミテッド 診断及び治療剤
EP1885393A4 (en) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIA INFECTIONS
US8227573B2 (en) 2005-05-20 2012-07-24 University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants
US7528232B2 (en) 2005-05-20 2009-05-05 The University Of Kentucky Research Foundation Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in crop plants
CN101217971B (zh) 2005-07-05 2011-11-09 比奥滕普特公司 肿瘤的治疗
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
WO2007019062A2 (en) 2005-08-11 2007-02-15 The Scripps Research Institute Zinc finger binding domains for cnn
US8445641B2 (en) 2005-08-22 2013-05-21 The United States Of America As Represented By The Secretary Of The Air Force Nanocomposites of repeat sequence proteins and phyllosilicate clays and their preparation
WO2007027954A2 (en) 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
EP1945658A4 (en) 2005-09-22 2012-05-30 Yeda Res & Dev DIASTEREOMERS PEPTIDES FOR MODULATING T-CELL IMMUNITY
ES2527961T3 (es) 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8137670B2 (en) 2005-09-29 2012-03-20 Medimmune, Llc Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
ES2546016T3 (es) 2005-10-13 2015-09-17 Biocon Limited Procedimiento para la preparación de conjugados de insulina
US7575876B2 (en) 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
UA96139C2 (ru) 2005-11-08 2011-10-10 Дженентек, Інк. Антитело к нейропилину-1 (nrp1)
CA2628708C (en) 2005-11-08 2011-11-29 Tohoku University Method of quantifying membrane protein by using mass spectrometer
US8252338B2 (en) 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle
EP1963499A4 (en) 2005-11-28 2009-04-08 Scripps Research Inst ZINCFINGER BINDING DOMAIN FOR TNN
GB0524313D0 (en) 2005-11-29 2006-01-04 Imp College Innovations Ltd Particles
EP1866329B1 (en) 2005-12-16 2010-05-26 National Cancer Center Peptides for inhibiting transglutaminase
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20090246283A1 (en) 2006-02-23 2009-10-01 Danisco Us Inc., Genecor Division Repeat Sequence Protein Polymer Nanoparticles Optionally Containing Active Agents and Their Preparation
JP4831370B2 (ja) 2006-02-28 2011-12-07 独立行政法人科学技術振興機構 グルカン量を低減させることなくリグニン量およびセルロース量を低減させた植物体およびその生産方法、並びにこれらの利用
US7501557B1 (en) 2006-02-28 2009-03-10 University Of Kentucky Research Foundation Method utilizing the tobacco phylloplanin promoter for expression of nucleic acids as gene products directed to aerial surfaces of plants
WO2007104062A2 (en) 2006-03-09 2007-09-13 The Board Of Regents Of The University Of Texas System Compositions and methods based on peptide binding profiling
WO2007108205A1 (ja) 2006-03-17 2007-09-27 Sanyo Chemical Industries, Ltd. 細胞培養用担体
EP1996609B1 (en) 2006-03-22 2016-08-03 The Scripps Research Institute Method of preparing glycopeptides
WO2007126876A2 (en) 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-igf-ir antibodies and uses thereof
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2021467A4 (en) 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
FR2900826B1 (fr) 2006-05-12 2008-08-15 Soc Extraction Principes Actif Utilisation de peptides en tant que principes actifs amincissants.
WO2007146319A2 (en) 2006-06-13 2007-12-21 Symphony Medical, Inc. Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications
KR20090031938A (ko) 2006-07-05 2009-03-30 더 스크립스 리서치 인스티튜트 방향성 진화로 촉매 작용을 최적화시킨 키메라 징크 핑거 리컴비나제
JP2010507069A (ja) 2006-07-08 2010-03-04 ユニバーシティー オブ ケンタッキー リサーチ ファンデーション 肺癌診断アッセイ
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP2008094822A (ja) 2006-09-15 2008-04-24 Univ Of Tokyo セルロース結合性ペプチドおよびその製造方法
US8771714B2 (en) 2006-10-31 2014-07-08 Musc Foundation For Research Development Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions
AU2007322252A1 (en) 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
ITTO20060852A1 (it) 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
KR101775929B1 (ko) 2007-01-19 2017-09-07 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
US9175422B2 (en) 2007-01-22 2015-11-03 The United States Of America As Represented By The Secretary Of The Army Polymer-micelle complex as an aid to electrospinning
CA2676797C (en) 2007-01-29 2014-04-22 Dae Woong Jo Novel macromolecule transduction domains and methods for identification and uses thereof
CL2008000493A1 (es) 2007-02-16 2008-06-27 Genentech Inc Polipeptido que se une especificamente a un dominio pdz de la proteina htra1; polinucleotido que lo codifica; metodo de produccion; anticuerpo que se une a el; y su uso para tratar patologias relacionadas con la proteina htra1.
CA2680824C (en) 2007-03-14 2018-06-26 Arch Therapeutics, Inc. Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
WO2008112904A2 (en) 2007-03-15 2008-09-18 Invitrogen Corporation Adhering surfaces
CA2681177C (en) 2007-03-19 2019-08-20 National Research Council Of Canada Antagonists of ligands and uses thereof
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
JP2008263955A (ja) 2007-03-29 2008-11-06 Sanyo Chem Ind Ltd 無血清培地
US20080306001A1 (en) 2007-04-04 2008-12-11 Anzelika Liik Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
US20090142839A1 (en) 2007-05-04 2009-06-04 Shiloh Laboratories, Inc. Inducing Premature Senescence to Stabilize Stem Cell Feeder Layer Cells
US8097581B2 (en) 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
US20090176664A1 (en) 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
EP2009023A1 (en) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
EP2155810A4 (en) 2007-06-13 2013-07-03 Fmc Corp ALGINATE-COATED, POLYSAC-CHARIDE-CONTAINING FOAM COMPOSITE, MANUFACTURING METHOD AND USES THEREOF
US20090017460A1 (en) 2007-06-15 2009-01-15 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2167136B1 (en) 2007-07-12 2016-04-20 BioMarin Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
TWI439286B (zh) 2007-07-16 2014-06-01 Genentech Inc 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2009020101A1 (ja) 2007-08-06 2009-02-12 University Of Tsukuba 花の形態が改変された植物体の生産方法
WO2009023125A1 (en) 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
CN101918007B (zh) 2007-08-28 2014-06-04 Fmc有限公司 延迟的自胶凝藻酸盐体系及其应用
CN101918556B (zh) 2007-09-04 2013-06-12 株式会社普罗赛尔制药 可穿透细胞的nm23重组蛋白、编码其的多核苷酸以及包含其的抗转移组合物
KR100887266B1 (ko) 2007-09-04 2009-03-06 주식회사 프로셀제약 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물
JP5000439B2 (ja) 2007-09-19 2012-08-15 三洋化成工業株式会社 細胞培養用担体
RU2010115088A (ru) 2007-09-20 2011-10-27 Дзе Дж. Дуйвид Гладстоун Инститьютс (Us) Композиции на основе line-полипептида и способы их применения
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
KR101577935B1 (ko) 2007-10-11 2015-12-16 다이이찌 산쿄 가부시키가이샤 파골 세포 관련 단백질 Ｓｉｇｌｅｃ-15 를 표적으로 한 항체
GB0720156D0 (en) 2007-10-15 2007-11-28 Univ Nottingham Trent Breast cancer associated antigen
EP2205623B1 (en) 2007-10-29 2016-03-16 Helix Biomedix Inc. Protective skin care tetrapeptides
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
DK2208073T3 (da) 2007-11-05 2020-03-30 Nordic Bioscience As Biokemiske markører til cvd-risikovurdering
WO2009061130A2 (en) 2007-11-06 2009-05-14 Procell Therapeutics Inc. Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same
EP2217614A4 (en) 2007-11-07 2011-12-07 Dynamic Microbials Ltd ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND APPLICATIONS THEREOF
US20100240057A1 (en) 2007-11-08 2010-09-23 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia
ES2395784T3 (es) 2007-11-12 2013-02-15 Theraclone Sciences, Inc. Composiciones y métodos para la terapia y diagnosis de la influenza
FR2925500B1 (fr) 2007-12-21 2011-05-06 Vincience Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
FR2925501B1 (fr) 2007-12-21 2012-12-14 Vincience Peptide activateur de la synthese des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
WO2009090651A2 (en) 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
US11260133B2 (en) 2008-02-21 2022-03-01 Sanford-Burnham Medical Research Institute Methods and compositions related to peptides and proteins with C-terminal elements
US20090298707A1 (en) 2008-03-18 2009-12-03 The Regents Of The University Of California Sparse matrix system and method for identification of specific ligands or targets
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20090281038A1 (en) 2008-05-09 2009-11-12 University Of Kentucky Research Foundation Phylloplanins Inhibition of Microbial Growth on Organic Materials
WO2009139599A2 (ko) 2008-05-16 2009-11-19 주식회사 프로셀제약 세포투과성 p27 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물
WO2010000794A1 (en) 2008-07-04 2010-01-07 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same by overexpressing a polynucleotide encoding a tfl1-like protein
SI2853545T1 (sl) 2008-09-17 2016-10-28 Xencor Inc., Protitelesa, specifična za IgE
JP5299956B2 (ja) 2008-09-29 2013-09-25 国立大学法人東北大学 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010102175A1 (en) 2009-03-05 2010-09-10 Medarex, Inc. Fully human antibodies specific to cadm1
SG10201401331TA (en) 2009-04-09 2014-10-30 Daiichi Sankyo Co Ltd Anti-siglec-15 antibody
SG184452A1 (en) 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
CN103237813A (zh) * 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体
MX2014011828A (es) 2012-03-30 2014-12-10 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
JP6268173B2 (ja) 2012-07-19 2018-01-24 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体

Also Published As

Publication number Publication date
KR20150036274A (ko) 2015-04-07
WO2014012165A1 (en) 2014-01-23
EP2875051A1 (en) 2015-05-27
CA2876517C (en) 2019-01-08
JP2015524256A (ja) 2015-08-24
MX2015000863A (es) 2016-05-05
US20150139982A1 (en) 2015-05-21
AU2013293062A1 (en) 2014-07-24
CA2928851A1 (en) 2014-01-23
HK1210192A1 (en) 2016-04-15
IN2014KN02933A (ru) 2015-05-08
ES2723885T3 (es) 2019-09-03
CN104507969A (zh) 2015-04-08
US9493562B2 (en) 2016-11-15
ZA201409358B (en) 2015-12-23
JP6268173B2 (ja) 2018-01-24
CA2876517A1 (en) 2014-01-23
EP2875051A4 (en) 2016-06-08
EP2875051B1 (en) 2019-02-20
IL236259A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
EA201590247A1 (ru) Антитела к siglec-15
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA202193044A2 (ru) Способы лечения таупатии
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
MY166776A (en) Humanised anti-ctla4 antibodies
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
MY157109A (en) Antibodies to human gdf8
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201400579A1 (ru) Антитела к il-36r
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
TR201907261T4 (tr) DKK-1 antikorları.
PH12014501613A1 (en) Anti-asic1 antibodies and uses thereof
EA201391312A1 (ru) Антитело к человеческому тканевому фактору и его применение
EA201400447A1 (ru) АНТИТЕЛА К CD1d